LABORATORY RESEARCH Inhibition of Androgen Receptor and β-Catenin Activity in Prostate Cancer Scientists provide proof-of-concept that a small-molecule inhibitor of nuclear β-catenin activity can inhibit both the androgen receptor and β-catenin-signaling pathways that are often misregulated in prostate cancer. [Proc Natl Acad Sci USA] Abstract TBK1 Regulates Prostate Cancer Dormancy through mTOR Inhibition Researchers investigated the effects of TANK binding kinase 1 (TBK1) on prostate cancer (PCa) dormancy in the bone marrow niche. They found that binding with niche osteoblasts induces the expression of TBK1 in PCa cells PC3 and C4-2B. [Neoplasia] Full Article Selectively Targeting Prostate Cancer with Antiandrogen Equipped Histone Deacetylase Inhibitors Investigators present the first example of histone deacetylase inhibitor compounds targeted to prostate tumors by equipping them with the additional ability to bind the androgen receptor with non-steroidal antiandrogen moieties. [ACS Chem Biol] Abstract The HDAC Inhibitor LBH589 Induces ERK-Dependent Prometaphase Arrest in Prostate Cancer via HDAC6 Inactivation and Down-Regulation Researchers determined if a potent histone deacetylase inhibitor (HDACI), LBH589, had differential therapeutic responsiveness towards LNCaP and PC-3 prostate cancer cells. The former showed prometaphase arrest with subsequent apoptosis upon LBH589 treatment, while the latter was less sensitive and had late G2 arrest. [PLoS One] Full Article Nanoparticulate Paclitaxel Demonstrates Antitumor Activity in PC3 and Ace-1 Aggressive Prostate Cancer Cell Lines Nanoparticulate paclitaxel was as effective as standard paclitaxel in decreasing cell viability, decreasing colony forming ability, and inducing apoptosis in human and canine prostate cancer cells in a dose-dependent manner. [Invest New Drugs] Abstract Functional and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide and Docetaxel Regimen in Castration-Resistant Prostate Cancer Scientists investigated the association of docetaxel and metronomic cyclophosphamide (CYC) in castration-resistant prostate cancer. Metronomic CYC is an effective adjuvant in blocking tumor growth in vivo, with comparable efficacy and less toxic effects compared with docetaxel treatment. [Future Oncol] Abstract Flavonoids from Orostachys japonicus A. Berger Inhibit the Invasion of LnCaP Prostate Carcinoma Cells by Inactivating Akt and Modulating Tight Junctions Researchers investigated the effects of flavonoids extracted from Orostachys japonicus A. Berger (FEOJ) on tight junctions and the expression of claudins as well as cancer invasion within LnCaP human prostate cancer. FEOJ suppressed cancer cell motility and invasiveness at the concentrations where FEOJ did not show anti-proliferative activity. [Int J Mol Sci] Abstract | Full Article CLINICAL RESEARCH Hypofractionated Intensity-Modulated Arc Therapy for Lymph Node Metastasized Prostate Cancer: Early Late Toxicity and 3-Year Clinical Outcome The authors evaluated clinical outcome, gastro-intestinal and genito-urinary toxicity after intensity modulated arc radiotherapy and androgen deprivation for N1 prostate cancer. [Radiother Oncol] Abstract G84E Mutation in HOXB13 Is Firmly Associated with Prostate Cancer Risk: A Meta-Analysis In an attempt to confirm and expand the findings that the prostate cancer (PCa) risk increased in men carrying G84E, researchers performed a meta-analysis to clarify the association between the germline G84E mutation and PCa risk. They also aimed to verify the increased PCa risk with respect to diagnostic age, family history, and disease aggressiveness. [Tumor Biol] Abstract |